A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Trial Details

NCT ID
NCT06522828
Phase
PHASE2
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SSGJ-707
  • carboplatin
  • paclitaxel
Locations (sample)
  • Chongqing, China|29.56026,106.55771

Key Eligibility Criteria

  • Age:18-75 years old
  • Advanced endometrial cancer and platinum-resistant ovarian cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Expected survival \>=12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →